Salarius Pharmaceuticals, Inc. announced a Third Amendment to its merger agreement with Decoy Therapeutics on July 18, 2025, allowing Decoy's noteholders to exchange debt for new preferred stock, leading to stockholder ownership of 7.6% for Salarius and 92.4% for Decoy after the merger. This event is significant as it modifies terms related to equity and potential control of the merged entity.